Core Viewpoint - The company announced a transaction involving the acquisition of a 50% stake in a subsidiary from ADM Singapore for a total price of 47 million yuan [1] Group 1 - The full subsidiary involved in the transaction is Qingdao Weilan Biological Group Co., Ltd. [1] - The acquired entity is Aidi Meng Weilan Biotechnology (Shandong) Co., Ltd. [1] - The transaction is part of the company's strategic moves to enhance its business operations [1]

Core Viewpoint - Blue Biological (603739.SH) announced that its wholly-owned subsidiary, Qingdao Blue Biological Group Co., Ltd., plans to sign a share transfer agreement with Archer Daniels Midland Singapore, Pte. Ltd. to acquire a 50% stake in ADM Blue Biological Technology (Shandong) Co., Ltd. for a transaction price of 47 million yuan [1] Group 1 - The transaction involves the acquisition of a 50% equity stake in ADM Blue Biological by Blue Biological Group [1] - The purchase price for the stake is set at 47 million yuan [1] - The agreement is part of Blue Biological's strategic expansion efforts in the biotechnology sector [1]

Group 1 - The company announced that its board received a resignation letter from Mr. You Shujun, the securities affairs representative, due to personal reasons [1] - Mr. You Shujun's resignation will take effect from the date it was delivered to the board, and he will no longer hold any position within the company [1] - The work previously managed by Mr. You Shujun has been successfully handed over, and his resignation will not impact the company's ongoing operations [1]

Group 1 - The core point of the article is that Blue Bio (603739) announced its intention to acquire a 50% stake in ADM Singapore's subsidiary, Aidi Meng Blue, for a transaction price of 47 million yuan [1] Group 2 - The acquisition is part of Blue Bio's strategy to expand its business operations and enhance its market position [1] - The transaction reflects Blue Bio's ongoing efforts to strengthen partnerships within the industry [1] - The deal is expected to contribute positively to Blue Bio's financial performance in the future [1]

格隆汇2月10日丨蔚蓝生物(603739.SH)公布，公司董事会于近日收到证券事务代表游淑军先生提交的书 面辞职报告，游淑军先生因个人原因申请辞去公司证券事务代表职务，辞职报告自送达公司董事会之日 起生效。游淑军先生辞职后将不再担任公司任何职务。截至本公告披露日，游淑军先生所负责的工作已 完成交接，其辞职不会影响公司相关工作的开展。 ...

Core Viewpoint - The company, Weilan Bio (603739), primarily focuses on the domestic market, with approximately 92% of its revenue coming from domestic operations [1] Group 1: Domestic and International Market Focus - The company's business is mainly concentrated in the domestic market, with a revenue share of about 92% from domestic operations [1] - The overseas markets include the United States, European Union, Philippines, Egypt, and Brazil, but the revenue from these markets is relatively low [1] - Sales to the EU market are primarily conducted by domestic entities directly selling to EU customers, contributing a minor portion to overall revenue [1] Group 2: Compliance and Disclosure - The company commits to adhering to the Shanghai Stock Exchange's listing rules and will fulfill its information disclosure obligations in a timely manner [1] - Relevant information will be disclosed on the Shanghai Stock Exchange's website, ensuring transparency for investors [1]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-002 青岛蔚蓝生物股份有限公司 关于为全资子公司提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 被担保人名称 | 本次担保金额 | | 实际为其提供的 担保余额（不含本 | | 是否在前期预计 | 本次担保是否有 反担保 | | --- | --- | --- | --- | --- | --- | --- | | | | | 次担保金额） | | 额度内 | | | 青岛蔚蓝生物集团 有限公司 | 4,000.00 | 万元 | 25,410.48 | 万元 | 是 | 否 | | 潍坊康地恩生物科 技有限公司 | 3,000.00 | 万元 | 7,153.98 | 万元 | 是 | 否 | | 青岛蔚蓝动物保健 集团有限公司 | 1,350.00 | 万元 | 4,980.00 | 万元 | 是 | 否 | 担保对象及基本情况 累计担保情况 | 对外担保逾期的累计金额（万元） | 0.00 | | --- | --- ...

Group 1 - Shoukai Co. achieved a signed area of 125.72 million square meters and a signed amount of 17.845 billion yuan in 2025 [1] - Tongda Hai expects a net loss for the year 2025 [2] - Jiuri New Materials' subsidiary has entered the trial production phase for a project with an annual capacity of 350 tons of hydroxy ketone [3] Group 2 - Jixin Technology's shareholder plans to reduce their stake by up to 1% [4] - Fulai New Materials received approval from the CSRC for a stock issuance [5] - Yaqi International plans to sign a strategic cooperation framework agreement with Zhongnong Holdings [6] Group 3 - Sanwei Co.'s controlling shareholder plans to transfer up to 5.10% of shares [7] - Lekai Film's subsidiary plans to invest 97.6675 million yuan in a TAC functional film production line [8] - China Power Construction's subsidiary signed two major contracts totaling approximately 15.589 billion yuan [9] Group 4 - Shunhao Co. plans to increase its investment in a subsidiary by 74.98 million yuan [10] - Jieneng Wind Power reported a cumulative power generation of 12.417 billion kWh in 2025, a year-on-year increase of 1.43% [11] - Zhongjian Technology's H-share issuance application has been accepted by the CSRC [12] Group 5 - Hendi Pharmaceutical expects a net profit decrease of 57.4% to 66.14% in 2025 [13] - Haopeng Technology anticipates a net profit increase of 113.69% to 141.09% in 2025 [14] - Lingang Co. expects a net loss of 1.45 billion to 1.67 billion yuan in 2025 [15] Group 6 - Chuan Investment Energy reported a cumulative power generation of 6.627 billion kWh in 2025, a year-on-year increase of 13.85% [16] - Tengyuan Cobalt expects a net profit increase of 50.02% to 69.87% in 2025 [17] - Huazhi Jie plans to repurchase shares worth 30 million to 50 million yuan [18] Group 7 - Opto has won a bid for a 120 million yuan project from GoerTek [19] - Shanghai Construction reported a new contract amount of 252.942 billion yuan in 2025, a year-on-year decrease of 34.98% [20] - Hangfa Control expects a net profit decrease of 52.02% to 58.02% in 2025 [22] Group 8 - Shimao Energy is planning a change in control and will continue to suspend trading [23] - Shenwan Hongyuan Securities received approval for a bond issuance of up to 60 billion yuan [24] - Jingjiawei signed a strategic cooperation letter of intent with Jing'an Technology [25] Group 9 - Pianzaihuang completed the first subject enrollment for a clinical trial of a new drug [26] - Placo's subsidiary received a new veterinary drug registration certificate [27] - Zhongli Co. plans to reduce its stake by up to 0.75% [28] Group 10 - Solar Energy received renewable energy subsidies of 3.318 billion yuan in 2025, a year-on-year increase of 142.9% [29] - Palm Co. has filed a lawsuit to recover 144 million yuan in project payments [30][31] - Yongjin Co. plans to invest 2.658 billion yuan in a new stainless steel project [32] Group 11 - BAIC Blue Valley plans to increase its stake by 14.5 million to 16.4 million yuan [33] - Lingyun Light's stock issuance application has been approved by the CSRC [34] - Hongbo New Materials expects a net loss in 2025 [35] Group 12 - Shanghai Pharmaceuticals received approval for the listing of a new antifungal drug [36] - Changjiang Electric reported a net profit of 34.167 billion yuan in 2025, a year-on-year increase of 5.14% [37] - Weilan Bio received a new veterinary drug registration certificate [38] Group 13 - Pingzhi Information's subsidiary is expected to win a procurement project worth approximately 37.5884 million yuan [39]

Market Overview - The chemical products sector experienced a decline of 0.29% on January 13, with Qiaoyuan Co. leading the drop [1] - The Shanghai Composite Index closed at 4138.76, down 0.64%, while the Shenzhen Component Index closed at 14169.4, down 1.37% [1] Top Performers - Huaheng Biological (688639) saw a significant increase of 13.79%, closing at 41.34 with a trading volume of 419,600 shares and a transaction value of 1.721 billion [1] - Chenghe Technology (688625) rose by 12.29%, closing at 62.32 with a trading volume of 109,000 shares and a transaction value of 672 million [1] - Kaisa Biological (688065) increased by 12.14%, closing at 62.24 with a trading volume of 177,800 shares [1] Underperformers - Qiaoyuan Co. (301286) fell by 8.67%, closing at 47.41 with a trading volume of 53,000 shares and a transaction value of 258 million [2] - Hangqing Co. (002430) decreased by 6.99%, closing at 32.06 with a trading volume of 311,600 shares [2] - Taihe Technology (300801) dropped by 6.72%, closing at 30.39 with a trading volume of 173,200 shares [2] Capital Flow - The chemical products sector saw a net outflow of 642 million from institutional investors and 357 million from retail investors, while retail investors had a net inflow of 999 million [2] - The capital flow data indicates a mixed sentiment among different investor types within the sector [2] Individual Stock Capital Flow - Duoliangduo (002407) had a net inflow of 224 million from institutional investors, while it experienced a net outflow of 1.09 billion from retail investors [3] - Wanhu Chemical (600309) saw a net inflow of 189 million from institutional investors, with a net outflow of 76.596 million from retail investors [3] - Yahua Group (002497) had a net inflow of 154 million from institutional investors, while retail investors experienced a net outflow of 17.488 million [3]

证券代码：603739 证券简称：蔚蓝生物 公告编号：2026-001 青岛蔚蓝生物股份有限公司 关于获得新兽药注册证书的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 作用与用途：用于预防鸡新城疫、H9 亚型禽流感、禽腺病毒病（I 群，4 型）、 鸡传染性法氏囊病。免疫产生期为 14 日，1～3 周龄雏鸡免疫期为 4 个月，3 周 龄及以上鸡免疫期为 6 个月。 用法与用量：肌肉或皮下注射。1～3 周龄雏鸡，每只 0.3ml；3 周龄及以上 鸡，每只 0.5ml。 根据《兽药管理条例》和《兽药注册办法》等的相关规定，经农业农村部审 查，批准青岛蔚蓝生物股份有限公司（以下简称"公司"）及全资子公司青岛动 保国家工程技术研究中心有限公司、青岛蔚蓝动物保健集团有限公司与其他单位 联合申报的"鸡新城疫、禽流感（H9 亚型）、禽腺病毒病（I 群，4 型）、传染性 法氏囊病四联灭活疫苗（La Sota 株+TA 株+LC 株+VP2 蛋白）"为三类新兽药，并 于近日核发了《新兽药注册证书》（农业农村部公告第 987 号）。 一、新兽药 ...